- Home
- CPRX vs JPC Comparison
CPRX vs JPC Comparison
Compare CPRX & JPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPRX | JPC |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPRX | JPC |
|---|---|---|
| Price | $22.66 | $8.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.60 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 998.5K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | ★ 44.94 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $578,196,000.00 | N/A |
| Revenue This Year | $16.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | ★ 25.56 | N/A |
| 52 Week Low | $19.05 | $5.94 |
| 52 Week High | $26.58 | $7.36 |
Technical Indicators
Market Signals| Indicator | CPRX | JPC |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 56.83 |
| Support Level | $23.01 | $7.84 |
| Resistance Level | $23.92 | $8.09 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 47.29 | 86.84 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.